(3H)maraviroc
Especificaciones
376348-65-1Número CAS
4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamideNombre IUPAC
C29H41F2N5OFórmula química
513.7 g/molPeso molecular
(3H)maraviroc; [3H]maraviroc; RefChem:1050229; Maraviroc; 376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; MD6P741W8A; C29H41F2N5O; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; CHEMBL256907; CHEMBL584744; MVC; CHEMBL1201187; DTXSID8048949; CHEBI:63608; 4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; Cyclohexanecarboxamide,4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; NCGC00183109-02; 2414315-81-2; 4,4-difluoro-N-[(1S)-3-[(1R,3S,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Celsentri(TM); Selzentry(TM); 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide; 4,4-Difluoro-N-[(1s)-3-{(3-Exo)-3-[3-Methyl-5-(Propan-2-Yl)-4h-1,2,4-Triazol-4-Yl]-8-Azabicyclo[3.2.1]oct-8-Yl}-1-Phenylpropyl]cyclohexanecarboxamide; Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-; PRO 140 & Maraviroc; maravirocum; Maraviroc [INN:BAN:JAN]; UNII-MD6P741W8A; Rel-Maraviroc; HSDB 8021; Maraviroc, endo-; 4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-[(1S)-3-{(1R,3S,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}-1-phenylpropyl]cyclohexane-1-carboxamide; Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; UK-427,857 maraviroc (MVC); MARAVIROC [INN]; MARAVIROC [JAN]; MARAVIROC [MI]; [3H]UK 427,857; [3H]UK-427,857; MARAVIROC [VANDF]; A3C7SRV8DV; Epitope ID:231724; MARAVIROC [MART.]; MARAVIROC [WHO-DD]; SCHEMBL51991; Selzentry, UK 427857; GTPL803; GTPL806; MARAVIROC [EMA EPAR]; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; MLS006011960; orb1301149; SCHEMBL2177194; SCHEMBL4576508; MARAVIROC [ORANGE BOOK]; DTXCID5028875; Maraviroc, >=98% (HPLC); EX-A200; CHEBI:184662; GSNHKUDZZFZSJB-HLMSNRGBSA-N; GSNHKUDZZFZSJB-QUMGSSFMSA-N; GLXC-90148; 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; Tox21_113369; AC-558; BDBM50334986; BDBM50464147; BDBM50583789; EBC-11333; EBC-14811; EBC-27258; MFCD13188530; MFCD31536297; AKOS025402143; AKOS032946723; AKOS032960315; UK 427857-d6; CS-0366; DB04835; FM25017; NCGC00183109-01; 4,4-difluoro-N-((1S)-3-((1R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; AS-75265; exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; HY-13004; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; SMR004703532; CAS-376348-65-1; T6016; EN300-128501; EN300-7367238; EN300-22828861; F868938; Q421369; SR-01000942244; SR-01000942244-1; BRD-A23284911-001-02-4; Z1614451557; 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[(1S,5S)-3-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-phenyl-propyl}-amide; 4,4-difluoro-N-((1S)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-((S)-3-((1R,3S,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexane-1-carboxamide; 4,4-difluoro-N-((S)-3-((1S,3S,5R)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-((S)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-aza-bicyclo[3.2.1]octan-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,3R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-isopropyl-5-methyl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenyl-propyl]cyclohexanecarboxamide; 4,4-Difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboximidic acid; 4,4-Difluoro-N-[(1S)-3-[(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl-d6)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl] cyclohexanecarboxamide; 4,4-difluoro-N-[(1S)-3-[exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane-8-yl]-1-phenylpropyl]cyclohexane1-formamide; 4,4-difluoro-N-{(1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide; 4,4-diluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[(3-endo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-; MRVSinónimos
Productos que contienen (3H)maraviroc
MARAVIROC WAYMADE 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGMARAVIROC WAYMADE 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGMARAVIROC TARBIS 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGMARAVIROC TARBIS 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGCELSENTRI 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULACELSENTRI 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMARAVIROC WAYMADE 300 mg, comprimé pelliculéMARAVIROC WAYMADE 150 mg, comprimé pelliculéCELSENTRI 75 mg, comprimé pelliculéCELSENTRI 300 mg, comprimé pelliculéCELSENTRI 25 mg, comprimé pelliculéCELSENTRI 20 mg/ml, solution buvable
Página 1 de 2
Empresas que venden (3H)maraviroc
JM
Jiangsu Magic Biotechnology Co., LtdChinaTF
Tarbis Farma S.L.SpainVH
Viiv Healthcare B.V.NetherlandsWB
Waymade B.V.NetherlandsLC
LEAP CHEM CO., LTD.Página 1 de 2